Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is disease in which the immune system mistakenly attacks healthy tissues, resulting in inflammation and tissue damage. Current treatments are focused on suppression of the immune system, but these therapies can leave patients vulnerable to infection.

2 Mar 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Scientists identify specific cellular events that appear key to lupus

A team led by scientists at The Scripps Research Institute (TSRI) has identified specific cellular events that appear key to lupus, a debilitating autoimmune disease that afflicts tens of millions of people worldwide. The findings suggest that blocking this pathway in lupus-triggering cells could be a potent weapon against the disease.

5 Feb 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Immunosuppressive drugs do not increase risk of cancer in lupus patients

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC).

28 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Surgery poses cardiac risk to lupus women

Women with systemic lupus erythematosus are at significantly increased risk for short-term perioperative adverse cardiovascular events, find researchers.

17 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

New insights into relationship between autoimmunity and brain function

A study published in the current issue of Psychotherapy and Psychosomatics by a group of French investigators of the University of Paris unravels new insights as to the relationship between autoimmunity and brain function.

30 Nov 2012

Azathioprine exposure concerns raised for SLE mothers

Researchers have raised the possibility of an increased risk for developmental delay in the children of mothers who used azathioprine for systemic lupus erythematosus during pregnancy.

26 Nov 2012

Lupus may carry pregnancy complication risk

US researchers report that women with systemic lupus erythematosus have a twofold higher risk for developing preeclampsia than women without an autoimmune disease.

6 Nov 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Musculoskeletal ultrasound being increasingly used for diagnosis and management of rheumatic diseases

More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.

29 Oct 2012

UMass professor receives $1 million LRI grant for lupus research

The Lupus Research Institute (LRI) has named University of Massachusetts Medical School Professor of Medicine Ann Marshak-Rothstein, MD, one of two recipients of the first LRI Distinguished Innovator Awards.

17 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Belimumab has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). Products (AMNOG).

30 Aug 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012